Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Mar 1;203(5):531-532.
doi: 10.1164/rccm.202012-4300ED.

Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited

Peter Calverley  1
Affiliations
Editorial

Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited

Peter Calverley. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. - PubMed
    1. Calverley P, Vlies B. A rational approach to single, dual and triple therapy in COPD. Respirology. 2016;21:581–589. - PubMed
    1. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957–963. - PMC - PubMed
    1. Celli BR, Anderson JA, Cowans NJ, Crim C, Hartley BF, Martinez FJ, et al. Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease: a systematic review. Am J Respir Crit Care Med. [online ahead of print] 23 Sept 2020; DOI: 10.1164/rccm.202005-1854OC. - PMC - PubMed
    1. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2011;5:44–49. - PubMed